Hyperostosis: Difference between revisions
No edit summary |
Kiran Singh (talk | contribs) No edit summary |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 14: | Line 14: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
{{ | ==Overview== | ||
'''Hyperostosis''' is an excessive growth of [[bone]]. It may lead to [[exostosis]]. It occurs in many [[musculoskeletal disorders]]. | '''Hyperostosis''' is an excessive growth of [[bone]]. It may lead to [[exostosis]]. It occurs in many [[musculoskeletal disorders]]. | ||
| Line 21: | Line 21: | ||
It is the thickening of the cortical bone. | It is the thickening of the cortical bone. | ||
Hyperphosphatemia-hyperostosis syndrome (HHS) is a rare autosomal recessive metabolic disorder characterized by elevated serum phosphate levels and radiological evidence of cortical hyperostosis.<ref name=Frishberg>{{ cite journal |author=Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E |title=Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders |journal=J Mol Med. |year=2005 |month=Jan |volume=83 |issue=1 |pages=33-8 |pmid=15599692 }}</ref> | [[Hyperphosphatemia]]-hyperostosis syndrome (HHS) is a rare autosomal recessive metabolic disorder characterized by elevated serum phosphate levels and radiological evidence of cortical hyperostosis.<ref name=Frishberg>{{ cite journal |author=Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E |title=Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders |journal=J Mol Med. |year=2005 |month=Jan |volume=83 |issue=1 |pages=33-8 |pmid=15599692 }}</ref> HHS is caused by mutations in GALNT3.<ref name=Ichikawa>{{ cite journal |author=Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ |title=Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations |journal=J Clin Endocrinol Metab. |year=2007 |month=May |volume=92 |issue=5 |pages=1943-7 |pmid=17311862 }}</ref> | ||
===Causes=== | |||
===Drug Side Effect=== | |||
* [[Isotretinoin]] | |||
=References= | =References= | ||
{{reflist}} | {{reflist|2}} | ||
==See also== | ==See also== | ||
| Line 31: | Line 37: | ||
{{Osteochondropathy}} | {{Osteochondropathy}} | ||
[[Category:Gross pathology]] | [[Category:Gross pathology]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 18:29, 8 June 2015
| Hyperostosis | |
| ICD-10 | M85.8 |
|---|---|
| DiseasesDB | 30719 |
| MeSH | D015576 |
|
WikiDoc Resources for Hyperostosis |
|
Articles |
|---|
|
Most recent articles on Hyperostosis Most cited articles on Hyperostosis |
|
Media |
|
Powerpoint slides on Hyperostosis |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Hyperostosis at Clinical Trials.gov Clinical Trials on Hyperostosis at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Hyperostosis
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Hyperostosis Discussion groups on Hyperostosis Patient Handouts on Hyperostosis Directions to Hospitals Treating Hyperostosis Risk calculators and risk factors for Hyperostosis
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Hyperostosis |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Hyperostosis is an excessive growth of bone. It may lead to exostosis. It occurs in many musculoskeletal disorders.
It is the thickening of the cortical bone.
Hyperphosphatemia-hyperostosis syndrome (HHS) is a rare autosomal recessive metabolic disorder characterized by elevated serum phosphate levels and radiological evidence of cortical hyperostosis.[1] HHS is caused by mutations in GALNT3.[2]
Causes
Drug Side Effect
References
- ↑ Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E (2005). "Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders". J Mol Med. 83 (1): 33–8. PMID 15599692. Unknown parameter
|month=ignored (help) - ↑ Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ (2007). "Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations". J Clin Endocrinol Metab. 92 (5): 1943–7. PMID 17311862. Unknown parameter
|month=ignored (help)